

**Basingstoke, Southampton and Winchester  
District Prescribing Committee (DPC)**

**Recommendations of the meeting of Tuesday 13<sup>th</sup> August 2019**

**Supported or limited support e.g. Specialist recommendation**

**Clobetasone butyrate, oxytetracycline and nystatin cream (Trimovate)** - Based on evaluation of the evidence for efficacy, safety and cost effectiveness and taking into account expert opinion/experience, the Committee supports the use of Trimovate cream in accordance with its [product licence](#), i.e. short-term in steroid responsive disorders associated with candidal or bacterial infections. The Committee would consider Trimovate as suitable for all clinicians to prescribe but would suggest it should not usually be a first line option, and use should be restricted to specific clinical situations when other preparations may be less effective/safe. Its relatively high cost, limitations in antifungal spectrum of action (nystatin is not effective against dermatophytes), and safety concerns about combination products and overuse of topical antimicrobials should be conveyed to non-specialist prescribers. Consider adding to formularies as GREEN.

N.B. Trimovate should remain non-formulary for use in chronic wound management.

**Ertugliflozin with metformin and a DPP4-inhibitor** – the Committee supports use of this triple therapy regimen as an option for type 2 diabetes in accordance with [NICE TA583](#) and highlights to prescribers that ertugliflozin is currently the least expensive SGLT-2 inhibitor. NICE guidance states:

- *Ertugliflozin with metformin and a dipeptidyl peptidase 4 (DPP 4) inhibitor is recommended as an option for treating type 2 diabetes in adults when diet and exercise alone do not provide adequate glycaemic control if the disease is uncontrolled with metformin and a DPP 4 inhibitor and a sulfonylurea or pioglitazone is not appropriate.*
- *If patients and their clinicians consider ertugliflozin to be one of a range of suitable treatments, including canagliflozin, dapagliflozin and empagliflozin, the least expensive should be chosen.*

**DEKAs and Paravit-CF multivitamins** - Based on evaluation of the evidence for efficacy, safety and cost effectiveness, the Committee supports the use of DEKAs and Paravit-CF vitamin supplements for patients with cystic fibrosis with evidence of pancreatic insufficiency. These would be suitable for prescribing in primary care following recommendation by CF specialists and guidance on choice of formulation and dose. Consider adding to formularies as AMBER (specialist recommended).

**Melatonin – 1mg and 5mg prolonged release tablets (Slenyto)** are now available as a licensed preparation for the treatment of insomnia in children and adolescents aged 2-18 years with ASD and/or Smith-Magenis Syndrome (SMS) where sleep hygiene measures have been insufficient. Prescribers are reminded that locally use of melatonin is supported only for sleep disorders in children/adolescents with specialist recommendation in accordance with [Shared Care Guidelines](#) (i.e. AMBER on formularies). These guidelines will be updated to include Slenyto tablets. Note: non-specialist initiation of melatonin treatment, as well as use in adults or for other indications remains unsupported by the committee.

**Not supported**

**Doxylamine succinate and pyridoxine hydrochloride** gastro-resistant tabs (Xonvea) - for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. In line with the recent [SMC](#) and [AWMSG](#) recommendations, the Committee's decision ([Feb 2019](#)) not to support routine use of this preparation remains unchanged.

## **Other Information and formulary updates**

**Shared care guidelines** for Antipsychotic depot administration (long acting injection) - these are endorsed by the Committee for use by Southampton City CCG and Southern Health only

**Liothyronine (oral)** - the Committee noted the revised RMOG guidance on prescribing of liothyronine- see link for details <https://www.sps.nhs.uk/wp-content/uploads/2019/07/RMOG-Liothyronine-guidance-V2.6-final.pdf>

**Easy read medication review prompt** is available on the Widgit website and free to download. This resource is useful for people with a learning disability and their carers ahead of their annual health check

<https://widgit-health.com/easy-read-sheets/index.htm>

<https://widgit-health.com/download-files/medication-review/My%20Medication%20Review.pdf>

**Guidance documents are available [Here](#) (hosted by West Hampshire CCG)**

**Summarised on behalf of the District Prescribing Committee by Andrea White (Southampton City CCG)**